Immunotherapy of cerebrovascular amyloidosis in a transgenic mouse model

Lifshitz, Veronica, Weiss, Ronen, Benromano, Tali, Kfir, Einat, Blumenfeld-Katzir, Tamar, Tempel-Brami, Catherine, Assaf, Yaniv, Xia, Weiming, Wyss-Coray, Tony, Weiner, Howard L. and Frenkel, Dan 2012. Immunotherapy of cerebrovascular amyloidosis in a transgenic mouse model. Neurobiology of Aging 33 (2) , 432.e1-432.e13. 10.1016/j.neurobiolaging.2011.01.006

Full text not available from this repository.

Abstract

Cerebrovascular amyloidosis is caused by amyloid accumulation in walls of blood vessel walls leading to hemorrhagic stroke and cognitive impairment. Transforming growth factor-β1 (TGF-β1) expression levels correlate with the degree of cerebrovascular amyloid deposition in Alzheimer's disease (AD) and TGF-β1 immunoreactivity in such cases is increased along the cerebral blood vessels. Here we show that a nasally administered proteosome-based adjuvant activates macrophages and decreases vascular amyloid in TGF-β1 mice. Animals were nasally treated with a proteosome-based adjuvant on a weekly basis for 3 months beginning at age 13 months. Using magnetic resonance imaging (MRI) we found that while control animals showed a significant cerebrovascular pathology, proteosome-based adjuvant prevents further brain damage and prevents pathological changes in the blood-brain barrier. Using an object recognition test and Y-maze, we found significant improvement in cognition in the treated group. Our findings support the potential use of a macrophage immunomodulator as a novel approach to reduce cerebrovascular amyloid, prevent microhemorrhage, and improve cognition.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Neuroscience and Mental Health Research Institute (NMHRI)
Publisher:	Elsevier
ISSN:	0197-4580
Last Modified:	21 Aug 2019 02:21
URI:	https://orca.cardiff.ac.uk/id/eprint/92236

Citation Data

Cited 22 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item